- Home
- TOVX vs GTBP Comparison
TOVX vs GTBP Comparison
Compare TOVX & GTBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TOVX
- GTBP
- Stock Information
- Founded
- TOVX 2001
- GTBP 1965
- Country
- TOVX United States
- GTBP United States
- Employees
- TOVX N/A
- GTBP N/A
- Industry
- TOVX Biotechnology: Pharmaceutical Preparations
- GTBP Biotechnology: Pharmaceutical Preparations
- Sector
- TOVX Health Care
- GTBP Health Care
- Exchange
- TOVX Nasdaq
- GTBP Nasdaq
- Market Cap
- TOVX 4.7M
- GTBP 5.6M
- IPO Year
- TOVX 2006
- GTBP N/A
- Fundamental
- Price
- TOVX $1.18
- GTBP $2.33
- Analyst Decision
- TOVX Strong Buy
- GTBP Strong Buy
- Analyst Count
- TOVX 1
- GTBP 1
- Target Price
- TOVX $6.00
- GTBP $11.00
- AVG Volume (30 Days)
- TOVX 23.5K
- GTBP 30.4K
- Earning Date
- TOVX 05-06-2025
- GTBP 05-14-2025
- Dividend Yield
- TOVX N/A
- GTBP N/A
- EPS Growth
- TOVX N/A
- GTBP N/A
- EPS
- TOVX N/A
- GTBP N/A
- Revenue
- TOVX N/A
- GTBP N/A
- Revenue This Year
- TOVX N/A
- GTBP N/A
- Revenue Next Year
- TOVX N/A
- GTBP N/A
- P/E Ratio
- TOVX N/A
- GTBP N/A
- Revenue Growth
- TOVX N/A
- GTBP N/A
- 52 Week Low
- TOVX $1.03
- GTBP $1.72
- 52 Week High
- TOVX $12.25
- GTBP $10.66
- Technical
- Relative Strength Index (RSI)
- TOVX 44.04
- GTBP 49.06
- Support Level
- TOVX $1.08
- GTBP $2.10
- Resistance Level
- TOVX $1.21
- GTBP $2.46
- Average True Range (ATR)
- TOVX 0.07
- GTBP 0.19
- MACD
- TOVX 0.00
- GTBP -0.01
- Stochastic Oscillator
- TOVX 57.89
- GTBP 51.00
About TOVX Theriva Biologics Inc.
Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a lead clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system.
About GTBP GT Biopharma Inc.
GT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products in the United States. It is engaged in discovering, developing, and commercializing novel therapeutics from its proprietary product platform in a varied range of disease areas. The company mainly develops drugs focused on the treatment of cancer. Its TriKE (Tri-specific Killer Engager) platforms offer immuno-oncology products that can treat a range of hematologic malignancies, sarcoma, and solid tumors.